A supplemental application for Opdivo (nivolumab) was approved by the FDA on March 10, 2020. This approval, designated BLA 125554 S-78, was for an efficacy claim, as submitted by sponsor Bristol Myers Squibb.
What this means
This supplemental FDA approval for Opdivo (nivolumab) on March 10, 2020, signifies that the agency has reviewed and accepted additional efficacy data for the drug. Supplemental applications typically involve new indications, dosage regimens, or patient populations, or updates to existing efficacy claims. While the specific details of the indication or patient population covered by this particular supplemental approval (BLA 125554 S-78) are not provided in the immediate data, it confirms an expansion or modification of the drug's approved uses or claims based on new scientific evidence. This type of approval is crucial for expanding the utility of established therapies. Clinicians and researchers should consult the official prescribing information and label updates for Opdivo to understand the precise scope and implications of this efficacy approval for patient care and future research directions.
Source
The information regarding this supplemental approval was sourced from the U.S. Food and Drug Administration (FDA). The approval of supplemental application BLA 125554 S-78 for Opdivo (nivolumab) was recorded on March 10, 2020, and is accessible on the accessdata.fda.gov website.